Mannkind (MNKD) risk factors, FY2024 10-K

RISKS RELATED TO OUR BUSINESS

1. 01The products that we or our collaboration partner are commercializing may only achieve a limited degree of commercial success
2. 02marketing and distribution support
3. 03In order to increase adoption and sales of our products, we need to continue to develop our commercial organization, including maintaining and growing a highly experienced and skilled workforce with qualified sales representatives
4. 04unforeseen delays, costs and expenses associated with maintaining our sales organization
5. 05Manufacturing risks may adversely affect our ability to manufacture our products and Tyvaso DPI, which could reduce our gross margin and profitability
6. 06These risks may be exacerbated by our limited experience with V-Go and its manufacturing processes
7. 07If third-party payers do not cover our approved products, such products might not be prescribed, used or purchased, which would adversely affect our revenues
8. 08We may need to raise additional capital to fund our operations
9. 09the costs of discontinuing projects and technologies, and/or decommissioning existing facilities, if we undertake any such activities
10. 10We expect that our results of operations will fluctuate for the foreseeable future, which may make it difficult to predict our future performance from period to period
11. 11We may incur losses and may not generate positive or sufficient cash flow from operations in the future which may have an adverse impact on our working capital, total assets and stockholders' equity and our ability to service all of our indebtedness and commitments
12. 12as a result of general disruptions in the operations of payers, distributors, logistics providers and other third parties that are necessary for our products to be prescribed and reimbursed
13. 13Continued testing of our products and product candidates may not yield successful results, and even if it does, we may still be unable to successfully commercialize our current or future products
14. 14disruptions caused by geopolitical conflicts, man-made or natural disasters or public health pandemics or epidemics or other business interruptions
15. 15If we do not achieve our projected development goals in the timeframes we expect, our business, financial condition and results of operations will be harmed and the market price of our common stock and other securities could decline
16. 16The long-term safety and efficacy of approved products may differ from clinical studies, which could negatively impact sales and could lead to reputational harm or other negative effects
17. 17We may not realize the anticipated benefits of any future acquisition or strategic transaction; we may be unable to successfully integrate new products, technologies or businesses we may acquire
18. 18possible write-offs or impairment charges relating to acquired assets, businesses or joint ventures
19. 19Our products and product candidates may be rendered obsolete by rapid technological change
20. 20Reports of side effects or safety concerns in related technology fields or in other companies’ clinical studies could delay or prevent us from obtaining regulatory approval for our product candidates or negatively impact public perception of our approved products
21. 21If product liability claims are brought against us, we may incur significant liabilities and suffer damage to our reputation
22. 22If we lose any key employees, our operations and our ability to execute our business strategy could be materially harmed
23. 23If our internal controls over financial reporting are not considered effective, our business, financial condition and market price of our common stock and other securities could be adversely affected
24. 24Changes or modifications in financial accounting standards may harm our results of operations
25. 25Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
26. 26Our ability to use net operating loss carryforwards to offset future taxable income may be subject to limitations
27. 27Tax authorities may disagree with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or non-realization of expected benefits
28. 28We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm our results of operations or financial condition
29. 29We deal with hazardous materials and must comply with environmental laws and regulations, which can be expensive and restrict how we do business
30. 30We maintain our cash at financial institutions, often in balances that exceed federally insured limits

RISKS RELATED TO GOVERNMENT REGULATION

1. 31product sales and distribution
2. 32Even if we comply with regulatory requirements, we may not be able to obtain the labeling claims necessary or desirable for product promotion. We may also be required to undertake post-marketing studies
3. 33We are subject to stringent, ongoing government regulation
4. 34injunctions or the imposition of civil or criminal penalties
5. 35Healthcare legislation may make it more difficult to receive revenues
6. 36If we or any partner fails to comply with federal and state healthcare laws, including fraud and abuse and health information laws, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected
7. 37Our business could be negatively impacted by environmental, social and corporate governance ("ESG") matters or our reporting of such matters
8. 38Our portfolio of investment securities may require us to register with the SEC as an “investment company” in accordance with the Investment Company Act of 1940 (“‘40 Act”)

RISKS RELATED TO INTELLECTUAL PROPERTY

1. 39If we are unable to protect our proprietary rights, we may not be able to compete effectively, or operate profitably
2. 40If we become involved in lawsuits to protect or enforce our patents or the patents of our collaborators or licensors, we would be required to devote substantial time and resources to prosecute or defend such proceedings
3. 41If our technologies conflict with the proprietary rights of others, we may incur substantial costs as a result of litigation or other proceedings and we could face substantial monetary damages and be precluded from commercializing our products, which would materially harm our business and financial condition
4. 42A patent owner may claim that we are making, using, selling or offering for sale an invention covered by the owner’s patents and may go to court to stop us from engaging in such activities. Such litigation is not uncommon in our industry
5. 43We may not obtain trademark registrations for our potential trade names

RISKS RELATED TO OUR COMMON STOCK

1. 44Our stock price is volatile
2. 45the status of any legal proceedings or regulatory matters against or involving us or any of our executive officers and directors; and
3. 46If we fail to continue to meet all applicable listing requirements, our common stock may be delisted from the Nasdaq Global Market, which could have an adverse impact on the liquidity and market price of our common stock
4. 47Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
5. 48any action asserting a claim against us or any of our directors, officers or other employees that is governed by the internal affairs doctrine
6. 49Because we do not expect to pay dividends in the foreseeable future, you must rely on stock appreciation for any return on any investment in our common stock
7. 50Future sales of shares of our common stock in the public market, or the perception that such sales may occur, may depress our stock price and adversely impact the market price of our common stock and other securities
8. 51If other biotechnology and biopharmaceutical companies or the securities markets in general encounter problems, the market price of our common stock and other securities could be adversely affected
9. 52Unstable market, economic and geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price
10. 53Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event
11. 54Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations